Budget impact analysis of skytrofa for the treatment of pediatric growth hormone deficiency in a US health plan
The inclusion of lonapegsomatropin in the formulary of a US health plan can result in a significant reduction in total costs for the plan.
Authors
- Wahidullah Noori
- Emil Boller
- Alden Smith (ORCID: https://orcid.org/0000-0003-1582-534X)
- S. Raveendran (ORCID: https://orcid.org/0000-0002-2971-9620)
- J. Kleintjens (ORCID: https://orcid.org/0000-0003-4667-9349)
- Paul Miner
Institutions
- Ascendis Pharma (Denmark) (DK)
- Precision Research (United States) (US)
- IBS Precision Engineering (Netherlands) (NL)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1080/13696998.2025.2561472
- Primary Topic
- Childhood Cancer Survivors' Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00